NCT00532909 - Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Anal, Colon, and Rectal CancersColorectal NeoplasmsColon/Rectal Cancer

Interventions

DRUG

Vandetanib

100mg or 300mg By mouth every day continuous

DRUG

Capecitabine

Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.

DRUG

Oxaliplatin

dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.

DRUG

Bevacizumab

Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)

Trial Locations (1)

Stanford University School of Medicine, Stanford